Posted on: Wed, 18 Aug 2010 14:30:16 EDT
COLORADO SPRINGS, Colo., Aug 18, 2010 (GlobeNewswire via COMTEX) —
Cannabis Science Inc. (OTCBB: CBIS | PowerRating) a pioneering US biotech company developing pharmaceutical cannabis products, announces that on August 18, 2010, Cannabis Science signed with RockBrook Inc., its first manufacturing and development license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.
Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, "Importantly, unlike big pharma, Cannabis Science will be able to immediately begin using data acquired from RockBrook patients using Cannabis Science Brands to evaluate our medical marijuana prior to FDA clinical trials. We are enthusiastic that our relationship with Mr. Pasquale and RockBrook has been established under a licensing and manufacturing agreement that is compliant with the current Colorado regulatory environment. RockBrook will immediately begin marketing
and developing new Cannabis Science Brand of Pharmaceutical Products."
Under the terms of the Agreement RockBrook will pay Cannabis Science an initial license fee of USD $25,000, which is payable within the first year of the Agreement. As well, RockBrook will pay Cannabis Science a quarterly royalty payment of 50% of all positive revenues derived from the Cannabis Science Brand of Pharmaceutical Products. If RockBrook enters into any sublicensing agreements, Cannabis Science is entitled to royalty payments of 50% of all positive revenues received by the Licensee for sales of any Cannabis Science Brand of Pharmaceutical Products. Within 2 years of the execution of this Agreement RockBrook will invest a minimum of $250,000 in research and development directly associated with the Cannabis Science Brand of Pharmaceutical Products. RockBrook will also pay to Cannabis Science a yearly renewable license fee, payable annually on the anniversary of the execution of this Agreement, according to the following schedule; First Anniversary payment USD $25,000, Second Anniversary USD $50,000, Third Anniversary USD $75,000, Fourth Anniversary USD $100,000, Fifth and Successive Anniversaries USD $150,000.
Richard Cowan, Cannabis Science CFO, added, "Due to changes in Colorado Legislation, Cannabis Science was forced to cancel the Share Purchase and Management Consulting Agreements previously signed on May 8, 2010 with RockBrook and its sole shareholder, Mr. Adam Pasquale. On August 1, 2010, the HB 1284 legislation came into effect in the State of Colorado. The new legislation precludes any non-resident from having ownership in a Colorado-based medical cannabis dispensary. Due to the broad ownership of Cannabis Science, a public company with shareholders around the world, and the fact that no specific element(s) of the new Colorado legislation permits or inures the same resident-based ownership rights to a public company, the Company’s legal counsel advised management to cancel the May 8th RockBrook acquisition, which Mr. Pasquale also agreed with. On July 30, 2010, we signed a Mutual Termination Agreement ("MTA") with RockBrook Inc. and its sole shareholder, Mr. Adam Pasquale. We are pleased that a mutually beneficial business relationship was reached with Mr. Pasquale and RockBrook, Inc. under the new legislation regulating Medical Marijuana in the State of Colorado."
About RockBrook, Inc.,www.RockBrookInc.com
Our dispensary prides itself in providing the highest quality medical marijuana medicines. When the question of potency is out of the way, the patient can better identify the right strain(s) to find an optimal balance. RockBrook also welcomes edibles from Gaea’s Harvest and other infused products made with Cannabis Science, Inc. oversight! We look forward to meeting all of you and providing you the type of experience you deserve! Our premium quality medicines include RockBrook BlueBerry (50/50), Afghani Kush (AK), White Widow, The Pink, Sour Diesel, Pineapple, Sweet Island Skunk, Maui Wowie, Flow, BlueCheese, BigWreck as well as a variety of proprietary strains. We are located near the intersection of S. Colorado Blvd and Yale. Our office is in the Robinson Law Building (across from SunFlower Market) on S. Colorado Blvd. We are open from 11:00am to 6:00pm (Tuesday to Saturday) Please call in advance for an appointment to ensure that we can provide you with the time you deserve! RockBrook, Inc. 2865 S. Colorado Blvd, Suite 323, Denver, CO 80222. Phone – 303.756.0595 firstname.lastname@example.org
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based Cannabis Science Brand of Pharmaceutical Products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Cannabis Science, Inc.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
Mark J. Friedman